AstraZeneca: positive results for Tagrisso
(CercleFinance.com) - Results from a Phase III clinical trial have showed that AstraZeneca's Tagrisso "significantly" improved the survival of previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations.
In a statement, the pharmaceutical company said that these "Today's positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care".
Lung cancer is currently the most deadly cancer in both men and women, representing about one in five cancer deaths.
Tagrisso is currently approved in 64 countries for the treatment of adult patients with metastatic non-small cell lung cancer with EGFR mutation.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In a statement, the pharmaceutical company said that these "Today's positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care".
Lung cancer is currently the most deadly cancer in both men and women, representing about one in five cancer deaths.
Tagrisso is currently approved in 64 countries for the treatment of adult patients with metastatic non-small cell lung cancer with EGFR mutation.
Copyright (c) 2019 CercleFinance.com. All rights reserved.